Skip to content

Engaging the Experts – A New Landscape: Biosimilars in Multiple Sclerosis

Health economics of disease-modifying therapy for multiple sclerosis in the United States

A place for biosimilars in the changing multiple sclerosis treatment

Multiple Sclerosis Biosimilars Landscape

Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab being developed to treat relapsing forms of MS including clinicallyContinue reading “Multiple Sclerosis Biosimilars Landscape”

Approved Risk Evaluation and Mitigation Strategies (REMS)

Natalizumab REMS Strategy

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Best Practices in Multiple Sclerosis Therapies